Boston Scientific Aktie 913577 / US1011371077
101.07
USD
2.20
USD
2.23%
18:43:39
BTT
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Boston Scientific Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2024 | Boston Scientific Corp. | 0.00 | 0.00 | USD |
| 2023 | Boston Scientific Corp. | 0.00 | 0.00 | USD |
| 2022 | Boston Scientific Corp. | 0.00 | 0.00 | USD |
| 2021 | Boston Scientific Corp. | 0.00 | 0.00 | USD |
| 2020 | Boston Scientific Corp. | 0.00 | 0.00 | USD |
| 2019 | Boston Scientific Corp. | 0.00 | 0.00 | USD |
| 2018 | Boston Scientific Corp. | 0.00 | 0.00 | USD |
| 2017 | Boston Scientific Corp. | 0.00 | 0.00 | USD |
| 2016 | Boston Scientific Corp. | 0.00 | 0.00 | USD |
| 2015 | Boston Scientific Corp. | 0.00 | 0.00 | USD |
Gewinn je Aktie- Boston Scientific
| 1.2 24 | 1.1 23 | 0.4 22 | 0.7 21 | -0.1 20 | 3.3 19 | 1.2 18 |
Umsatz je Aktie- Boston Scientific
| 11.3 24 | 9.7 23 | 8.8 22 | 8.3 21 | 7.0 20 | 7.6 19 | 7.0 18 |
KGV- Boston Scientific
| 71.6 24 | 53.9 23 | 104 22 | 61.8 21 | 13.6 19 | 29.7 18 |
Boston Scientific Corp.: Die Aktie (in USD)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (berichtet) | 1.25 | 1.07 | 0.45 | 0.69 | -0.08 | 3.33 | 1.19 |
| Gewinn je Aktie (unverwässert) | 1.26 | 1.08 | 0.45 | 0.69 | -0.08 | 3.38 | 1.21 |
| Gewinn je Aktie (verwässert) | 1.25 | 1.07 | 0.45 | 0.69 | -0.08 | 3.33 | 1.19 |
| Dividende je Aktie | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Veränderung Dividende je Aktie in % | - | - | - | - | - | - | - |
| Gesamtdividendenausschüttung in Mio. | 0.00 | 28.00 | 55.00 | 55.00 | 28.00 | 0.00 | 0.00 |
Boston Scientific Corp.: Unternehmenskennzahlen (in USD)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 11.27 | 9.73 | 8.81 | 8.29 | 7.00 | 7.61 | 7.01 |
| KGV (Jahresendkurs, Gewinn unverwässert) | 71.62 | 53.89 | 103.77 | 61.83 | - | 13.57 | 29.70 |
| KGV (Jahresendkurs, Gewinn verwässert) | 71.62 | 53.89 | 103.77 | 61.83 | - | 13.57 | 29.70 |
| Dividendenrendite Jahresende in % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Eigenkapitalquote in % | 55.85 | 55.58 | 54.12 | 51.57 | 49.80 | 45.40 | 41.55 |
| Fremdkapitalquote in % | 44.15 | 44.42 | 45.88 | 48.43 | 50.20 | 54.60 | 58.45 |
Boston Scientific Corp.: GuV (in Mio. USD)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 16’747.00 | 14’240.00 | 12’682.00 | 11’888.00 | 9’913.00 | 10’735.00 | 9’823.00 |
| Umsatzveränderung in % | 17.61 | 12.29 | 6.68 | 19.92 | -7.66 | 9.28 | 8.57 |
| Bruttoergebnis vom Umsatz | 10’267.00 | 8’831.00 | 7’714.00 | 7’461.00 | 5’576.00 | 6’879.00 | 6’477.00 |
| Bruttoergebnisveränderung in % | 16.26 | 14.48 | 3.39 | 33.81 | -18.94 | 6.21 | 10.32 |
| Operatives Ergebnis | 2’635.00 | 2’181.00 | 1’824.00 | 1’922.00 | 601.00 | 1’712.00 | 1’737.00 |
| Veränderung Operatives Ergebnis in % | 20.82 | 19.57 | -5.10 | 219.80 | -64.89 | -1.44 | 13.90 |
| Ergebnis vor Steuern | 2’282.00 | 1’985.00 | 1’141.00 | 1’076.00 | -79.00 | 687.00 | 1’422.00 |
| Veränderung Ergebnis vor Steuern in % | 14.96 | 73.97 | 6.04 | - | - | -51.69 | 52.41 |
| Ergebnis nach Steuer | 1’854.00 | 1’593.00 | 698.00 | 1’040.00 | -82.00 | 4’700.00 | 1’671.00 |
| Veränderung Ergebnis nach Steuer in % | 16.38 | 128.22 | -32.88 | - | - | 181.27 | 1’506.73 |
Boston Scientific Corp.: Bilanz (in Mio. USD)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Fremdkapital | 17’392 | 15’606 | 14’896 | 15’607 | 15’450 | 16’688 | 12’273 |
| Langzeit Gesamtverbindlichk. je Aktie | 7.46 | 7.28 | 7.74 | 7.95 | 8.31 | 8.48 | 5.07 |
| Eigenkapital | 22’003 | 19’530 | 17’573 | 16’622 | 15’327 | 13’877 | 8’726 |
| Veränderung Eigenkapital in % | 12.90 | 9.73 | 5.72 | 8.45 | 10.45 | 59.03 | 24.44 |
| Bilanzsumme | 39’395 | 35’136 | 32’469 | 32’229 | 30’777 | 30’565 | 20’999 |
| Veränderung Bilanzsumme in % | 12.12 | 8.21 | 0.74 | 4.72 | 0.69 | 45.55 | 10.28 |
Boston Scientific Corp.: Sonstige Angaben (in USD)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | 1.26 | 1.08 | 0.45 | 0.69 | -0.08 | 3.38 | 1.21 |
| Veränderung Gewinn je Aktie (unverwässert) in % | 16.55 | 140.75 | -35.19 | - | -102.40 | 179.14 | 1’412.50 |
| Gewinn je Aktie (verwässert) | 1.25 | 1.07 | 0.45 | 0.69 | -0.08 | 3.33 | 1.19 |
| Veränderung Gewinn je Aktie (verwässert) in % | 16.25 | 140.59 | -35.09 | - | -102.44 | 179.99 | 1’493.04 |
| Anzahl Mitarbeiter | 53’000 | 48’000 | 45’000 | 41’000 | 38’000 | 36’000 | 32’000 |
| Veränderung Anzahl Mitarbeiter in % | 10.42 | 6.67 | 9.76 | 7.89 | 5.56 | 12.50 | 10.34 |
Boston Scientific Corp. Termine
| Unternehmen | Event | Datum |
|---|---|---|
| Boston Scientific Corp. | Hauptversammlung | 01.05.2025 |
| Boston Scientific Corp. | Quartalszahlen | 23.07.2025 |
| Boston Scientific Corp. | Quartalszahlen | 22.10.2025 |
| Boston Scientific Corp. | Quartalszahlen | 04.02.2026 |
| Boston Scientific Corp. | Quartalszahlen | 29.04.2026 |
Boston Scientific Corp. vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q1 2025 Earnings Release | 23.04.2025 |
| Quartalszahlen | Q4 2024 Earnings Release | 05.02.2025 |
| Quartalszahlen | Q3 2024 Earnings Release | 23.10.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 24.07.2024 |
| Hauptversammlung | Annual General Meeting | 02.05.2024 |
| Quartalszahlen | Q1 2024 Earnings Release | 24.04.2024 |
| Quartalszahlen | Q4 2023 Earnings Release | 31.01.2024 |
| Quartalszahlen | Q3 2023 Earnings Release | 26.10.2023 |
| Quartalszahlen | Q2 2023 Earnings Release | 27.07.2023 |
| Hauptversammlung | Annual General Meeting | 04.05.2023 |
| Quartalszahlen | Q1 2023 Earnings Release | 26.04.2023 |
| Quartalszahlen | Q4 2022 Earnings Release | 01.02.2023 |
| Quartalszahlen | Q3 2022 Earnings Release | 26.10.2022 |
| Quartalszahlen | Q2 2022 Earnings Release | 27.07.2022 |
| Hauptversammlung | Annual General Meeting | 05.05.2022 |
| Quartalszahlen | Q1 2022 Earnings Release | 27.04.2022 |
| Quartalszahlen | Q4 2021 Earnings Release | 02.02.2022 |
Personal
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 32’000 | 36’000 | 38’000 | 41’000 | 45’000 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.31 | 0.30 | 0.26 | 0.29 | 0.28 |
Bilanz (in Mio. USD) - Aktiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 4’002 | 4’699 | 6’694 | 6’317 | 5’760 |
| Summe Anlagevermögen | 16’997 | 25’866 | 24’083 | 25’912 | 26’709 |
| Summe Aktiva | 20’999 | 30’565 | 30’777 | 32’229 | 32’469 |
Bilanz (in Mio. USD) - Passiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 12’273 | 16’688 | 15’450 | 15’607 | 14’896 |
| Summe Eigenkapital | 8’726 | 13’877 | 15’327 | 16’622 | 17’573 |
| Summe Passiva | 20’999 | 30’565 | 30’777 | 32’229 | 32’469 |
Adresse
| 300 Boston Scientific Way, 01752-1234 Marlborough | |
| Telefon | +1 (508) 683-4000 |
| URL | http://www.bostonscientific.com |
Management
|
Arthur Crosswell Butcher
EVP, Group President-MedSurg & Asia Pacific |
|
Charles J. Dockendorff
Independent Director |
|
Charlie Attlan
SVP-New Business Development, Strategy & Portfolio |
|
Cheryl B. Pegus
Independent Director |
|
Colin Morrison
Director-Business Development & Venture Capital |
|
Daniel J. Brennan
Chief Financial Officer & Executive Vice President |
|
David C. Habiger
Independent Director |
|
David Scott Wichmann
Independent Director |
|
Edward J. Ludwig
Lead Independent Director |
|
Ellen M. Zane
Independent Director |
|
Emily Woodworth
Chief Accounting Officer, SVP & Controller |
|
Eric Francis Yves Thepaut
EVP, President-Europe, Middle East & Africa |
|
Jeffrey B. Mirviss
Executive VP & President-Peripheral Interventions |
|
Jessica L. Mega
Independent Director |
|
Jim Cassidy
Vice President & Franchise Lead-Pain Management |
|
Jodi Eddy
Senior VP, Chief Information & Digital Officer |
|
John Bradley Sorenson
Executive Vice President-Global Operations |
|
John Edward Sununu
Independent Director |
|
Jonathan Richard Monson
Senior Vice President-Investor Relations |
|
Joseph M. Fitzgerald
Executive VP & Group President-Cardiology |
|
June Chang
President-Greater China |
|
Kathryn Graves Unger
Vice President-Environmental, Social & Governance |
|
Kenneth Stein
Global Chief Medical Officer & Senior VP |
|
Mark Bickel
VP-Finance & Global Controller-Rhythm Management |
|
Mary Beth Moynihan
Chief Marketing Officer & Senior VP-Market Access |
|
Meghan M. Scanlon
President-Urology & Senior Vice President |
|
Michael F. Mahoney
Chairman, President & Chief Executive Officer |
|
Michael Jones
President-Endoscopy & Senior Vice President |
|
Milad Girgis
Vice President & Franchise Lead |
|
Miriam O’Sullivan
Chief Human Resources Officer & Senior VP |
|
Nicholas Spadea-Anello
President-Electrophysiology & Senior VP |
|
Rosaleen Burke
Senior Vice President-Global Quality & Regulatory |
|
Samuel Conaway
President-US Sales Cardiology Group |
|
Susan E. Morano
Independent Director |
|
Susan J. Thompson
Chief Corporate Counsel, VP & Assistant Secretary |
|
Vance Ronald Brown
Secretary, Senior Vice President & General Counsel |
|
Yoshiaki Fujimori
Independent Director |